Dear Editor,
Prothymosin-α1 (ProTα), a highly acidic nuclear protein of the α-thymosin family, has multiple functions both within and outside of the cell.1 ProTα plays a cytoprotective role by inhibiting apoptosome formation,2 and it has cell proliferative activity as an extracellular signaling molecule.1 Recently, we found that ProTα is released upon necrotic stress and protects cells from neuronal death through activation of a putative Gi/o-coupled receptor coupled to phospholipase C and protein kinase CβII.3
Following stroke or traumatic damages, both necrotic and apoptotic neuronal death cause loss of functions including memory, sensory perception and motor skills.4, 5 Necrosis occurs during the early stages of stroke and of the affected area expands with time,6 whereas the apoptosis occurs with some delay, but may also have a potential role in restricting the spread of irretrievable damage.6, 7 There have been many attempts to find compounds that inhibit apoptosis, but the protective potencies of these compounds against ischemic damage in vivo remain limited.8, 9, 10, 11 This may be related to the possibility that rapid and expanding necrosis largely contributes to the total loss of brain neurons following ischemia. Thus, rapid treatment of stroke is currently emphasized.11, 12, 13 Compared with the machinery involved in apoptosis, necrosis is a more passive process, in which energy failure leads to a rupture of the plasma membrane with concomitant loss of intracellular proteins and ions.6 However, no compounds that inhibit necrosis are known. Here, we demonstrate that ProTα has potential therapeutic utility against the necrosis component of stroke.
In the focal ischemic model of middle cerebral artery occlusion (MCAO, 1 h) followed by reperfusion in the rat, a marked loss of triphenyltetrazolium chloride (TTC) staining, which detects the presence of mitochondrial enzymes, was observed specifically in the ipsilateral regions of the cerebral cortex, hippocampus and striatum at 24 h after reperfusion (Figures 1a–1d). Systemic administrations of recombinant rat ProTα (rrProTα, 100 μg/kg, i.p.) at 30 min and 3 h after reperfusion, largely reversed this brain damage and suppressed ischemia-induced motor dysfunction, evaluated by a so-called clinical score,14 and lethality (Figures 1f and 1g). It should be noted that ProTα protected the brain from cell death and motor dysfunction when administered as a single injection (at 30 min or 3 h after reperfusion) or in a pair of later injections (at 3 and 6 h after reperfusion). In a sublethal global ischemic model using both common carotid artery occlusions (BCCAO, 30 min), there were marked losses of neurons in the pyramidal cell layers and dentate gyri of surviving mice at 28 days after occlusion (Figure 1(h). A single systemic (i.p.) injection of recombinant mouse ProTα (rmProTα) at 100 μg/kg 24 h after occlusion completely prevented brain damage, learning and memory deficits in the step-through passive avoidance task, and lethality (Figures 1i–k). Significant prevention was also observed with rmProTα at a very low dose, 1 μg/kg (i.p.).
By cytochemical analysis, both necrosis and apoptosis were observed in damaged brain regions 24 h after MCAO, when cell death was evaluated by in vivo propidium iodide and activated-caspase 3 staining. Systemic rrProTα injection (i.p.) markedly inhibited both necrotic and apoptotic cell death (Figures 1l–1o).
It should be noted that ProTα inhibited both necrosis and apoptosis following ischemia. This finding contrasts with our recent study, in which ProTα was shown to inhibit necrosis by restoring the reduced membrane translocation of glucose transporters under ischemic conditions in a primary culture of cortical neurons, but to cause apoptosis through upregulation of proapoptotic Bax and Bim.3 However, complete inhibition of cell death was observed when ischemic neurons were co-treated with ProTα and antiapoptotic neurotrophins, the expression levels of which are upregulated in in vivo ischemic models.15 In fact, the treatment with anti-BDNF or anti-EPO IgG (1 μg each) into the subarachnoid space through a parietal bone, 30 min before MCAO stress, reversed ProTα-inhibited apoptosis, but not necrosis (Figures 1p and q).
A single or paired injection of ProTα through a systemic route is sufficient to completely prevent damage in brain ischemic models. As shown in Figure 1r, a significant amount of Myc-tagged rrProTα, which had been administered i.p., was detected in the cortex 3 h after MCAO stress. The neuroprotective actions of ProTα administered through systemic routes are likely to be due to the transient disruption of the blood–brain barrier in the ischemic brain.16 It is worth to note that the neuroprotective actions of ProTα were observed when injected systemically 3 h after the ischemia, a time point within the therapeutic window for the treatment of stroke with tissue plasminogen activator. The fact that neurons are the major sites of action for ProTα is also expected to be advantageous in the treatment of stroke.
The paper by Shiau et al.17 described that added ProTα is incorporated into the cell and nuclei to ‘enhance’ the cytokine gene transcription and increase the infarct volume through inflammatory actions, whereas ProTα mutant lacking nuclear localizing sequence (NLS) ‘inhibits’ it. As shown in the Figure 1r, Myc-ProTα incorporated into the brain does not seem to be degraded and lose C-terminal NLS. Therefore, the finding by Shiau et al.17 is unlikely related to the ProTα-induced cell death inhibition in this study. Furthermore, in our previous study,3 there was no significant difference in the survival activity between ProTα and its mutant lacking C-terminal NLS.
Thus, ProTα is a unique cell death regulatory molecule, in that it converts irretrievable necrotic cell death into controllable apoptosis. Because this apoptosis can be inhibited by growth factors secreted upon ischemic stress, it is expected that ProTα may have an overall neuroprotective roles in the treatment of stroke.
References
Pineiro A, Cordero OJ, Nogueira M . Peptides 2000; 21: 1433–1446.
Jiang X et al. Science 2003; 299: 223–226.
Ueda H et al. J Cell Biol 2007; 176: 853–862.
Dirnagl U, Iadecola C, Moskowitz MA . Trends Neurosci 1999; 22: 391–397.
Lipton P . Physiol Rev 1999; 79: 1431–1568.
Ueda H, Fujita R . Biol Pharm Bull 2004; 27: 950–955.
Danial NN, Korsmeyer SJ . Cell 2004; 116: 205–219.
Brines ML et al. Proc Natl Acad Sci USA 2000; 97: 10526–10531.
Cheng Y et al. J Clin Invest 1998; 101: 1992–1999.
Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D . Pharmacol Rev 2002; 54: 271–284.
Gladstone DJ, Black SE, Hakim AM . Stroke 2002; 33: 2123–2136.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581–1587.
Borsello T et al. Nat Med 2003; 9: 1180–1186.
Kagiyama T et al. Stroke 2004; 35: 1192–1196.
Hughes PE et al. Prog Neurobiol 1999; 57: 421–450.
Paul R et al. Nat Med 2001; 7: 222–227.
Shiau AL et al. J Immunol 2007; 178: 4688–4694.
Acknowledgements
We are grateful to M Ueda, H Matsunaga and N Kiguchi for technical assistance. Parts of this study were supported by Grants-in-Aid for Scientific Research (to HU, B: 13470490, B: 15390028), Special Coordination Funds (to HU, 17025031) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and Encouragement of Young Scientists (to RF, B: 17790066) from the Japan Society for the Promotion of Science (JSPS).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Supplementary information
Rights and permissions
About this article
Cite this article
Fujita, R., Ueda, H. Prothymosin-α1 prevents necrosis and apoptosis following stroke. Cell Death Differ 14, 1839–1842 (2007). https://doi.org/10.1038/sj.cdd.4402189
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4402189
This article is cited by
-
Critical Functionality Effects from Storage Temperature on Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cell Suspensions
Scientific Reports (2019)
-
Deletion of Nuclear Localizing Signal Attenuates Proinflammatory Activity of Prothymosin-Alpha and Enhances Its Neuroprotective Effect on Transient Ischemic Stroke
Molecular Neurobiology (2017)
-
Subcellular dissemination of prothymosin alpha at normal physiology: immunohistochemical vis-a-vis western blotting perspective
BMC Physiology (2016)
-
Prothymosin α overexpression contributes to the development of pulmonary emphysema
Nature Communications (2013)
-
Stress-induced non-vesicular release of prothymosin-α initiated by an interaction with S100A13, and its blockade by caspase-3 cleavage
Cell Death & Differentiation (2010)